Title: Desire for Alternative Treatment Options in Patients with Atopic Dermatitis in Japan: Results of a Web-Based Cross-Sectional Study (AD-JOIN STUDY).

Authors: Takeshi Nakahara¹, Shunya Takemoto,² Hiroyuki Houzawa,² Masahiko Nakayama²

Affiliations: ¹Department of Dermatology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan; ²Medical Department, AbbVie GK, 3-1-21 Shibaura, Minato-ku, Tokyo, 108-0023, Japan

Corresponding Author:

Shunya Takemoto

3-1-21 Shibaura, Minato-ku,

Tokyo 108-0023, Japan

Email: shunya.takemoto@abbvie.com

ORCID ID: 0000-0002-7375-1417
**Supplementary Table 1.** Demographic and Baseline Clinical Characteristics

| Age category, years, n (%) | Analysis Set |
|---------------------------|--------------|
|                           | N=1,500      |
| <20                       | 5 (0.3)      |
| 20–<30                    | 222 (14.8)   |
| 30–<40                    | 483 (32.2)   |
| 40–<50                    | 464 (30.9)   |
| 50–<60                    | 244 (16.3)   |
| 60–<70                    | 67 (4.5)     |
| ≥70                       | 15 (1.0)     |

Relationship status, n (%)

---

### Notes:
- The table represents the demographic and baseline clinical characteristics of the analysis set with a total of 1,500 participants.
- The data is categorized by age groups and relationship status, with counts and percentages provided.
| Status         | Count | Percentage |
|----------------|-------|------------|
| Single         | 644   | 42.9%      |
| Married        | 856   | 57.1%      |

| Time since AD diagnosis, n (%) | Count | Percentage |
|-------------------------------|-------|------------|
| <2 weeks                      | 8     | 0.5%       |
| 2 weeks–<1 month              | 2     | 0.1%       |
| 1 month–<3 months             | 7     | 0.5%       |
| 3–<6 months                   | 4     | 0.3%       |
| 6 months–<1 year              | 10    | 0.7%       |
| 1–<2 years                    | 29    | 1.9%       |
| 2–<3 years                    | 30    | 2.0%       |
| 3–<4 years                    | 17    | 1.1%       |
| 4–<5 years                    | 22    | 1.5%       |
| ≥5 years                      | 1,371 | 91.5%      |
| Hospital clinical department, n (%)                      |        |
|---------------------------------------------------------|--------|
| Dermatology                                             | 1,402  |
| Internal medicine                                       | 61     |
| Pediatrics                                              | 5      |
| Other                                                   | 32     |

| Duration of topical corticosteroid use, n (%)            |        |
|---------------------------------------------------------|--------|
| <2 weeks                                                | 62     |
| 2 weeks--<1 month                                       | 22     |
| 1 month--<3 months                                      | 42     |
| 3--<6 months                                            | 41     |
| 6 months--<1 year                                       | 50     |
| 1--<2 years                                             | 82     |
| 2--<3 years                                             | 79     |
| Duration of outpatient care          | n (%) |
|-------------------------------------|-------|
| <2 weeks                            | 27 (1.8) |
| 2 weeks–<1 month                    | 14 (0.9) |

Topical corticosteroid strength, n (%)  

| Class Description                     | n (%)  |
|---------------------------------------|--------|
| Class 1 (Super potency)               | 205 (13.7) |
| Class 2 (High-potency)                | 814 (54.3) |
| Class 3 (Medium-to-high potency)      | 355 (23.7) |
| Class 4 (Medium potency)              | 570 (38.0) |
| Class 5 (Weak potency)                | 44 (2.9) |
| Unknown                               | 477 (31.8) |
| Age Group          | Number (Percentage) |
|-------------------|---------------------|
| 1 month--<3 months | 34 (2.3)            |
| 3--<6 months      | 50 (3.3)            |
| 6 months--<1 year | 69 (4.6)            |
| 1--<2 years       | 150 (10.0)          |
| 2--<3 years       | 138 (9.2)           |
| 3--<4 years       | 98 (6.5)            |
| 4--<5 years       | 61 (4.1)            |
| ≥5 years          | 859 (57.3)          |

AD, atopic dermatitis. Based on Katoh N et al. Japanese guidelines for atopic dermatitis 2020. *Allergol Int* 2020; 69(3): 356-369.
**Supplementary Table 2.** Bivariate Analysis of Patients with an Overall Desire, and Desire for Specific Type of Alternative Treatment

|                        | N    | Overall Desire | Desire for Specific Type of Alternative Treatment |
|------------------------|------|----------------|--------------------------------------------------|
|                        |      |                | Change in medication | Hospital transfer | CAM |
| Total, n               | 1,500| 1,372 (91.5) [90.1–92.9] | 1,213 (80.9) [78.9–82.9] | 429 (28.6) [26.3–30.9] | 593 (39.5) [37.1–42.0] |
| Sex                    |      |                |                    |                    |     |
| Female                 | 830  | 759 (91.4) [89.5–93.3] | 658 (79.3) [76.5–82.0] | 241 (29.0) [25.9–32.1] | 347 (41.8) [38.5–45.2] |
| Male                   | 670  | 613 (91.5) [89.4–93.6] | 555 (82.8) [80.0–85.7] | 188 (28.1) [24.7–31.5] | 246 (36.7) [33.1–40.4] |
| Age, years             |      |                |                    |                    |     |
| <30                    | 227  | 209 (92.1) [88.6–95.6] | 173 (76.2) [70.7–81.8] | 71 (31.3) [25.2–37.3] | 103 (45.4) [38.9–51.9] |
| Income Category | Count | Mean (SD) | Median (IQR) | Mean (SD) | Median (IQR) | Mean (SD) | Median (IQR) |
|----------------|-------|-----------|--------------|-----------|--------------|-----------|--------------|
| 30–<40         | 483   | 439 (90.9) | 380 (78.7)   | 140 (29.0) | 209 (43.3)   | 75.0–82.3 | 24.9–33.0    | 38.9–47.7    |
| 40–<50         | 464   | 429 (92.5) | 387 (83.4)   | 137 (29.5) | 168 (36.2)   | 80.0–86.8 | 25.4–33.7    | 31.8–40.6    |
| 50–<60         | 244   | 222 (91.0) | 205 (84.0)   | 60 (24.6)  | 85 (34.8)    | 79.4–88.6 | 19.2–30.0    | 28.9–40.8    |
| ≥60            | 82    | 73 (89.0)  | 68 (82.9)    | 21 (25.6)  | 28 (34.1)    | 74.8–91.1 | 16.2–35.1    | 23.9–44.4    |

Household income category, yen

| Income Category | Count | Mean (SD) | Median (IQR) | Mean (SD) | Median (IQR) | Mean (SD) | Median (IQR) |
|----------------|-------|-----------|--------------|-----------|--------------|-----------|--------------|
| <3.7 million   | 421   | 385 (91.4) | 326 (77.4)   | 118 (28.0) | 157 (37.3)   | 73.4–81.4 | 23.7–32.3    | 32.7–41.9    |
| 3.7–<7.7 million | 632  | 575 (91.0) | 509 (80.5)   | 179 (28.3) | 267 (42.2)   | 77.5–83.6 | 24.8–31.8    | 38.4–46.1    |
| 7.7–<11.6 million | 325  | 298 (91.7) | 270 (83.1)   | 102 (31.4) | 123 (37.8)   | 79.0–87.2 | 26.3–36.4    | 32.6–43.1    |
### Current hospital visit status

| Status  | Yes | No |
|---------|-----|----|
| Count   | 1,230 | 270 |
| Percentage | 93.0% | 84.4% |
| Range   | [89.1–97.8] | [80.1–88.8] |

### Duration of topical corticosteroid use

| Years   | ≥5 years | <5 years |
|---------|----------|----------|
| Count   | 1,035 | 465 |
| Percentage | 92.2% | 89.9% |
| Range   | [90.5–93.8] | [87.2–92.6] |

### Duration of outpatient care, n (%)

| Years   | ≥5 years | <5 years |
|---------|----------|----------|
| Count   | 859 | 780 |
| Percentage | 90.8% | 90.8% |
| Range   | [88.9–92.7] | [78.6–83.9] |
| Age Group | POEM Severity Classification | PP-NRS Severity Classification |
|-----------|------------------------------|-------------------------------|
| <5 years  |                              |                               |
|           | 641                          | 592 (92.4)                    |
|           | 515 (80.3)                   | 183 (28.5)                    |
|           | 271 (42.3)                   |                               |
|           | [90.3–94.4]                  | [77.3–83.4]                   |
|           | [25.1–32.0]                  | [38.5–46.1]                   |
| POEM severity classification | Mild                         |                               |
|           | 517                          | 435 (84.1) [81.0–87.3]        |
|           | 370 (71.6)                   | 119 (23.0)                    |
|           | 162 (31.3)                   |                               |
|           | [67.7–75.5]                  | [19.4–26.6]                   |
|           | [27.3–35.3]                  |                               |
|          | Moderate                      |                               |
|           | 656                          | 620 (94.5) [92.8–96.3]        |
|           | 549 (83.7)                   | 189 (28.8)                    |
|           | 279 (42.5)                   |                               |
|           | [80.9–86.5]                  | [25.3–32.3]                   |
|           | [38.7–46.3]                  |                               |
| Severe    | 246                          | 238 (96.7) [94.5–99.0]        |
|           | 217 (88.2)                   | 83 (33.7)                     |
|           | 113 (45.9)                   |                               |
|           | [84.2–92.2]                  | [27.8–39.6]                   |
|           | [39.7–52.2]                  |                               |
| Very severe | 81                           | 79 (97.5) [94.2–100.0]        |
|           | 77 (95.1)                    | 38 (46.9)                     |
|           | 39 (48.1)                    |                               |
|           | [90.3–99.8]                  | [36.0–57.8]                   |
|           | [37.3–59.0]                  |                               |
| PP-NRS severity classification | No itch                      |                               |
|           | 24                           | 15 (62.5) [43.1–81.9]         |
|           | 12 (50.0)                    | 4 (16.7)                      |
|           | 7 (29.2)                     |                               |
|           | [30.0–70.0]                  | [1.8–31.6]                    |
|           | [11.0–47.4]                  |                               |
| Itch Severity       | Total | PGIC Improvement |
|--------------------|-------|------------------|
|                    |       | Very much improved | Much improved | Minimally improved |
| Mild itch          | 696   | 600 (86.2) [83.6–88.8] | 513 (73.7) [70.4–77.0] | 164 (23.6) [20.4–26.7] | 230 (33.0) [29.6–36.5] |
| Moderate itch      | 487   | 468 (96.1) [94.4–97.8] | 421 (86.4) [83.4–89.5] | 142 (29.2) [25.1–33.2] | 201 (41.3) [36.9–45.6] |
| Severe itch        | 251   | 247 (98.4) [96.9–100.0] | 229 (91.2) [87.7–94.7] | 101 (40.2) [34.2–46.3] | 135 (53.8) [47.6–60.0] |
| Very severe itch   | 42    | 42 (100.0) [100.0–100.0] | 38 (90.5) [81.6–99.4] | 18 (42.9) [27.9–57.8] | 20 (47.6) [32.5–62.7] |

**PGIC classification, n (%)**

- **Very much improved**
  - Total: 94
  - PGIC: 71 (75.5) [66.8–84.2] 51 (54.3) [44.2–64.3] 11 (11.7) [5.2–18.2] 26 (27.7) [18.6–36.7]

- **Much improved**
  - Total: 460
  - PGIC: 405 (88.0) [85.1–91.1] 336 (73.0) [69.0–77.1] 87 (18.9) [15.3–22.5] 153 (33.3) [29.0–37.6]

- **Minimally improved**
  - Total: 630
  - PGIC: 595 (94.4) [92.7–96.2] 548 (87.0) [84.4–89.6] 217 (34.4) [30.7–38.2] 283 (44.9) [41.0–48.8]
| PGIT classification                        | Frequency | Percentage | Lower Confidence Limit | Upper Confidence Limit |
|--------------------------------------------|-----------|------------|------------------------|------------------------|
| No change                                  | 280       | 95.0%      | [84.4–92.0]            | [30.1–41.3]            |
| Minimally, much, or very much worse        | 36        | 97.2%      | [74.8–97.4]            | [23.0–54.8]            |
|                                            |           |            |                        | [28.2–60.7]            |
| PGIT classification                        |           |            |                        |                        |
| Extremely or very satisfied                | 136       | 64.0%      | [37.9–54.7]            | [11.9–24.9]            |
| Slightly satisfied                         | 341       | 87.4%      | [65.2–74.9]            | [9.9–17.1]             |
|                                            |           |            |                        | [24.2–33.8]            |
| Neither dissatisfied nor satisfied          | 502       | 94.6%      | [81.3–87.6]            | [22.8–30.6]            |
|                                            |           |            |                        | [31.7–40.1]            |
| Slightly dissatisfied                      | 389       | 98.2%      | [91.1–96.0]            | [40.0–49.9]            |
|                                            |           |            |                        | [47.7–57.7]            |
| Extremely or very dissatisfied              | 132       | 98.5%      | [88.9–97.5]            | [42.2–59.3]            |
|                                            |           |            |                        | [55.4–71.8]            |
| ADCT classification, n (%) |  |  |  |  |
|---------------------------|---|---|---|---|
| Good control              | 396 | 321 (81.1) [77.2–84.9] | 268 (67.7) [63.1–72.3] | 83 (21.0) [17.0–25.0] | 114 (28.8) [24.3–33.2] |
| Poor control              | 1,104 | 1,051 (95.2) [93.9–96.5] | 945 (85.6) [83.5–87.7] | 346 (31.3) [28.6–34.1] | 479 (43.4) [40.5–46.3] |

ADCT, Atopic Dermatitis Control Tool; CAM, complementary and alternative medicine; PGIC, Patient’s Global Impression of Change; PGIT, Patient’s Global Impression of Treatment; POEM, Patient-Oriented Eczema Measure; PP-NRS, Peak Pruritus Numerical Rating Scale.